Milan, Italy – Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active Pharmaceutical Ingredients, announced on thw 1st of December 2022 that its production site, located in Baranzate, just outside Milan (Italy), has received the Good Manufacturing Practice (GMP) certification, CBPF (Certificado de Boas Práticas de Fabricação), from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária). It is the first Dipharma manufacturing facility to receive ANVISA certification.

This authorization certifies the strict adherence of Dipharma’s quality system to GMP requirements and allows Dipharma to be the right choice for all customers who would like to register new applications at ANVISA. The facility has already been regularly and successfully inspected by the US FDA and the Italian Ministry of Health (AIFA) for more than 50 years.

“We are very pleased to have obtained this first successful completion of the ANVISA certification — said Jorge Nogueira, Chief Executive Officer of Dipharma Francis S.r.l. — It represents a key regulatory milestone for the Dipharma Group and demonstrates our continuous commitment to providing high quality services and solutions to our global customers”.

For more info: www.dipharma.com